How tau pathology changes with age
Tau pathology accumulates with age, but the relationship is not linear. This page maps what the experimental literature reports on tau hyperphosphorylation, aggregation and age-related vulnerability across in vitro, anim
Tau is a microtubule-associated protein encoded by the MAPT gene on chromosome 17; the adult human brain expresses six isoforms generated by alternative splicing of exons 2, 3 and 10, giving rise to 3R and 4R tau species. In its native state tau stabilises microtubules in axons, but hyperphosphorylation reduces its microtubule affinity and promotes its self-association into paired helical filaments and, ultimately, neurofibrillary tangles. Tau hyperphosphorylation is one of the core pathological drivers of Alzheimer's disease (AD), alongside amyloid-β accumulation, oxidative stress, neuroinflammation, mitochondrial dysfunction and cholinergic deficits [2].
The work described here centres on tau phosphorylation state and its downstream consequences for synaptic and network function, with the NAD+-mitophagy axis and synaptic plasticity modulators appearing as adjacent mechanistic themes in the same literature [5][6].
Research Studies
Tau hyperphosphorylation and age in the AD pathological cascade
Alzheimer's disease is described in the reviewed literature as a progressive neurodegenerative disorder in which tau hyperphosphorylation sits alongside amyloid-β accumulation, oxidative stress, neuroinflammation, mitochondrial dysfunction and cholinergic deficits as a defining feature of the disease process [2]. Ageing is reported as the strongest risk factor for AD, which places age at the centre of any account of how tau pathology develops over time [3]. The reviewed evidence does not describe tau phosphorylation as a simple function of chronological age; it is presented as one node in a multi-pathway cascade [2].
Davunetide (AL-108) and tauopathy patients
A pilot clinical study of davunetide (NAP, AL-108) was conducted in patients with predicted tauopathies — frontotemporal lobar degeneration (FTLD) with predicted tau pathology, corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy (PSP). The primary objective was to obtain preliminary safety and tolerability data. Secondary objectives included preliminary data on short-term changes at 12 weeks from baseline in clinical, functional and biomarker measurements, including cerebrospinal fluid (CSF) tau levels, eye movements and brain MRI measurements [4]. This is a pilot study design; the record describes objectives rather than outcomes.
Yamanaka factor expression and tauopathy in the P301S mouse
Targeted and intermittent expression of Yamanaka factors (YFs) in hippocampal neurons was investigated in the P301S mouse model of tauopathy. Controlled YFs expression in hippocampal neurons was reported to increase excitatory synaptic markers, and the work examined whether this restored cognitive function and neural network integrity [3]. This finding is animal-only and specific to the P301S model; it should not be read as a statement about human tauopathy progression.
NAD+-mitophagy axis in ageing and neurodegeneration
A combined artificial intelligence and wet-lab approach identified a role for the NAD+-mitophagy axis in ageing and neurodegeneration. The work was motivated by emerging evidence linking nicotinamide mononucleotide (NAD+) depletion and compromised mitophagy to ageing and neurodegenerative disease, and tested the hypothesis that age-dependent impairment of this axis contributes to brain ageing and neurodegeneration [5]. This is a mechanistic finding about an ageing-associated pathway rather than a direct measurement of tau burden.
Synaptic plasticity modulators and AD
Synaptic dysfunction is described as the earliest and most critical pathological feature of AD, contributing directly to cognitive decline. A review of the molecular and biochemical modulators governing synaptic plasticity discusses how their disruption in AD relates to the disease process [6]. This is a review-level synthesis; it supports the framing of tau-related synaptic loss rather than providing primary tau measurements.
Natural medicines and tau-relevant mechanisms
A bibliometric analysis and narrative review mapped publications in the Web of Science Core Collection from 1 January 2001 to 28 April 2025 on natural medicines for AD, using VOSviewer and CiteSpace, and then examined representative mechanistic evidence through a focused narrative synthesis [1]. A separate review synthesised in vitro, in vivo and clinical evidence on 15 medicinal plants and 21 active compounds with relevance to AD, including tau hyperphosphorylation among the pathways considered [2]. Both are syntheses of existing work rather than new primary data on age-related tau change.
Comparison of evidence types across the tau literature
| Model or population | What was examined | Evidence type |
|---|---|---|
| P301S mouse, hippocampal neurons | Yamanaka factor expression, excitatory synaptic markers, memory and neural synchrony [3] | Animal |
| Patients with predicted tauopathies (FTLD, CBS, PSP) | Safety, tolerability, CSF tau, eye movements, brain MRI at 12 weeks [4] | Clinical pilot |
| Ageing and neurodegeneration models | NAD+-mitophagy axis [5] | AI plus wet lab |
| AD literature 2001–2025 | Publication trends and mechanistic themes [1] | Bibliometric and narrative review |
| 15 medicinal plants, 21 compounds | AD-related pathways including tau hyperphosphorylation [2] | In vitro, in vivo and clinical synthesis |
Where the age relationship is and is not established
Across the sources above, age appears as a risk factor and as a modifier of the pathways in which tau sits, but the evidence does not support a single quantitative statement about how tau pathology changes per year of age. The P301S work is animal-only [3]; the davunetide record is a pilot study reporting objectives [4]; the NAD+-mitophagy and synaptic plasticity work addresses adjacent mechanisms rather than tau load directly [5][6]; and the natural medicine reviews are syntheses of heterogeneous studies [1][2].
If you are reading this for personal health reasons
The materials described on this page are sold for laboratory research use only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound for their own use should speak to a licensed clinician.
Sources
- [1] Research Trends and Mechanistic Insights Into Natural Medicines for Alzheimer's Disease: A Bibliometric Analysis and Narrative Review — https://pubmed.ncbi.nlm.nih.gov/42730515/
- [2] Translational potential of medicinal plants for Alzheimer's disease: integrated evidence from molecular mechanisms to preclinical and clinical findings — https://europepmc.org/article/PMC/PMC13338004
- [3] Targeted neuronal reprogramming rescues memory and neural synchrony in Alzheimer's disease — https://europepmc.org/article/PMC/PMC13253944
- [4] Davunetide (AL-108) in Predicted Tauopathies - Pilot Study — https://clinicaltrials.gov/study/NCT01056965
- [5] A combined artificial intelligence-wet lab approach identifies a pivotal role of the NAD+-mitophagy axis on aging and neurodegeneration — https://pubmed.ncbi.nlm.nih.gov/42626968/
- [6] Biochemical modulators of synaptic plasticity: New horizons in Alzheimer's disease treatment — https://europepmc.org/article/PMC/PMC13554379